Literature DB >> 22684555

Effect of TRPC6 knockdown on puromycin aminonucleoside-induced podocyte injury.

Xifeng Sun1,2, Yongli Chu3, Chun Zhang1, Xiyun Du2, Fangfang He1, Shan Chen1, Pan Gao1, Jianshe Liu1, Zhonghua Zhu1, Xianfang Meng4.   

Abstract

This study was aimed to construct eukaryotic expression vectors carrying the small hairpin RNA (shRNA) targeting TRPC6 gene and investigate the effect of TRPC6 knockdown on puromucin aminonucleoside (PAN)-induced podocyte injury. Two DNA sequences containing the small hairpin structure targeting TRPC6 were designed, synthesized and then inserted into the green fluorescence protein (GFP)-contained plasmids (pGC) to establish the plasmids pGCsi-TRPC6A and pGCsi-TRPC6B. Plasmids expressing scrambled shRNA were used as negative control and named pGCsi-NC. These plasmids were transfected into a conditionally immortalized murine podocyte cell line by using liposome. Flow cytometry was used to examine the transfection efficiency. TRPC6 mRNA and protein expression levels were detected by RT-PCR and Western blotting. Cultured podocytes were divided into four groups: control group, PAN treatment group, PAN+TRPC6 shRNA transfected group and PAN+scrambled shRNA transfected group. The paracelluar permeability to BSA was evaluated by Millicell-PCF Inserts and cell viability was measured by the trypan blue assay. Immunofluorescent assay was used to observe the distribution of α-actinin-4 and α-tubulin. The results showed that the transfection efficiency of the shRNA expression vector was about 45%. Expression levels of TRPC6 mRNA and protein were downregulated after transfection with pGCsi-TRPC6A and pGCsi-TRPC6B. Knocking down TRPC6 gene could effectively reverse the PAN-induced increase in the paracelluar permeability to BSA. The distribution of α-actinin-4 and α-tubulin was disrupted after treatment with PAN, which was reversed by knocking down TRPC6 gene. It was concluded that knocking down TRPC6 gene could effectively prevent podocytes from the permeability increase induced by PAN, which may be related to the regulation of podocyte cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684555     DOI: 10.1007/s11596-012-0059-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  16 in total

1.  Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis.

Authors:  J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function.

Authors:  Jochen Reiser; Krishna R Polu; Clemens C Möller; Peter Kenlan; Mehmet M Altintas; Changli Wei; Christian Faul; Stephanie Herbert; Ivan Villegas; Carmen Avila-Casado; Mary McGee; Hikaru Sugimoto; Dennis Brown; Raghu Kalluri; Peter Mundel; Paula L Smith; David E Clapham; Martin R Pollak
Journal:  Nat Genet       Date:  2005-05-27       Impact factor: 38.330

3.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

4.  Effect of down-regulation of TRPC6 on the puromycin aminonucleoside-induced apoptosis of mouse podocytes.

Authors:  Xifeng Sun; Zhan Fang; Zhonghua Zhu; Xiao Yang; Fangfang He; Chun Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

5.  Cultured podocytes establish a size-selective barrier regulated by specific signaling pathways and demonstrate synchronized barrier assembly in a calcium switch model of junction formation.

Authors:  Jennifer L Hunt; Martin R Pollak; Bradley M Denker
Journal:  J Am Soc Nephrol       Date:  2005-04-20       Impact factor: 10.121

6.  TRPC6 enhances angiotensin II-induced albuminuria.

Authors:  Jason Eckel; Peter J Lavin; Elizabeth A Finch; Nirvan Mukerji; Jarrett Burch; Rasheed Gbadegesin; Guanghong Wu; Brandy Bowling; Alison Byrd; Gentzon Hall; Matthew Sparks; Zhu Shan Zhang; Alison Homstad; Laura Barisoni; Lutz Birbaumer; Paul Rosenberg; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2011-01-21       Impact factor: 10.121

7.  A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.

Authors:  Michelle P Winn; Peter J Conlon; Kelvin L Lynn; Merry Kay Farrington; Tony Creazzo; April F Hawkins; Nikki Daskalakis; Shu Ying Kwan; Seth Ebersviller; James L Burchette; Margaret A Pericak-Vance; David N Howell; Jeffery M Vance; Paul B Rosenberg
Journal:  Science       Date:  2005-05-05       Impact factor: 47.728

8.  Induction of TRPC6 channel in acquired forms of proteinuric kidney disease.

Authors:  Clemens C Möller; Changli Wei; Mehmet M Altintas; Jing Li; Anna Greka; Takamoto Ohse; Jeffrey W Pippin; Maria P Rastaldi; Stefan Wawersik; Susan Schiavi; Anna Henger; Matthias Kretzler; Stuart J Shankland; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

9.  Adriamycin increases podocyte permeability: evidence and molecular mechanism.

Authors:  Xiaozhong Li; Haitao Yuan; Xueguang Zhang
Journal:  Chin Med J (Engl)       Date:  2003-12       Impact factor: 2.628

10.  [Role of CD2-associated protein in podocyte differentiation.].

Authors:  Hua-Jun Jiang; Ying Chang; Zhong-Hua Zhu; Jian-She Liu; An-Guo Deng; Chun Zhang
Journal:  Sheng Li Xue Bao       Date:  2008-02-25
View more
  2 in total

1.  TRPC5 Channel Inhibition Protects Podocytes in Puromycin-Aminonucleoside Induced Nephrosis Models.

Authors:  Yiming Zhou; Choah Kim; Juan Lorenzo B Pablo; Fan Zhang; Ji Yong Jung; Li Xiao; Silvana Bazua-Valenti; Maheswarareddy Emani; Corey R Hopkins; Astrid Weins; Anna Greka
Journal:  Front Med (Lausanne)       Date:  2021-09-21

Review 2.  Transient Receptor Potential Canonical (TRPC) Channels: Then and Now.

Authors:  Xingjuan Chen; Gagandeep Sooch; Isaac S Demaree; Fletcher A White; Alexander G Obukhov
Journal:  Cells       Date:  2020-08-28       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.